{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:10:46Z","timestamp":1784085046368,"version":"3.55.0"},"reference-count":23,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4,1]]},"DOI":"10.1210\/jc.2013-3318","type":"journal-article","created":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T21:58:50Z","timestamp":1387490330000},"page":"1282-1290","source":"Crossref","is-referenced-by-count":155,"title":["Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial"],"prefix":"10.1210","volume":"99","author":[{"given":"Philippe J.","family":"Caron","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolic Diseases (P.J.C.), Centre Hospitalier Universitaire Larrey, F-31059 Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Bevan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (J.S.B.), Aberdeen Royal Infirmary, Aberdeen AB25 2ZP, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Petersenn","sequence":"additional","affiliation":[{"name":"ENDOC Center for Endocrine Tumors (S.P.), 20357 Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (D.F.), Derriford Hospital, Plymouth PL6 8DH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Tabarin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, Metabolic Diseases, and Nutrition (A.T.), University of Bordeaux 2, CHU Bordeaux, 33076 Bordeaux, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebtan","family":"Pr\u00e9vost","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes, and Metabolic Diseases (G.P.), CHU Rouen, 76031 Rouen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Maisonobe","sequence":"additional","affiliation":[{"name":"Ipsen Pharma (P.M., A.C.), 92100 Boulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Clermont","sequence":"additional","affiliation":[{"name":"Ipsen Pharma (P.M., A.C.), 92100 Boulogne-Billancourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the PRIMARYS Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113431226100_B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.17.S4.1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly\u20132011 update","volume":"17","author":"Katznelson","year":"2011","journal-title":"Endocr Pract"},{"key":"key\n\t\t\t\t2019041113431226100_B2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1530\/eje.1.01863","article-title":"The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical \u2018cure\u2019","volume":"152","author":"Nomikos","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113431226100_B3","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"Melmed","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113431226100_B4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11102-010-0269-9","article-title":"Current management practices for acromegaly: an international survey","volume":"14","author":"Giustina","year":"2011","journal-title":"Pituitary"},{"key":"key\n\t\t\t\t2019041113431226100_B5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2265.2008.03503.x","article-title":"Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly","volume":"71","author":"Colao","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113431226100_B6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","article-title":"A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly","volume":"66","author":"Mercado","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113431226100_B7","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1210\/jc.2004-1093","article-title":"Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly","volume":"90","author":"Bevan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113431226100_B8","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1210\/jc.2006-2084","article-title":"Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient","volume":"92","author":"Resmini","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113431226100_B9","doi-asserted-by":"crossref","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019041113431226100_B10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11102-009-0169-z","article-title":"Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review","volume":"13","author":"Mazziotti","year":"2010","journal-title":"Pituitary"},{"key":"key\n\t\t\t\t2019041113431226100_B11","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1210\/jc.2004-2466","article-title":"A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly","volume":"90","author":"Melmed","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113431226100_B12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cct.2003.12.001","article-title":"Widening eligibility to phase II trials: constant arcsine difference phase II trials","volume":"25","author":"A'Hern","year":"2004","journal-title":"Control Clin Trials"},{"key":"key\n\t\t\t\t2019041113431226100_B13","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","article-title":"Standards of medical care in diabetes\u20132013","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t2019041113431226100_B14","first-page":"2779","article-title":"Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly","volume":"86","author":"Colao","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113431226100_B15","first-page":"4099","article-title":"Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)","volume":"85","author":"Baldelli","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113431226100_B16","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1210\/jc.2001-012012","article-title":"Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size","volume":"87","author":"Bevan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113431226100_B17","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1210\/jc.2009-2272","article-title":"Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial","volume":"95","author":"Petersenn","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113431226100_B18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2265.2008.03441.x","article-title":"Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study","volume":"70","author":"Colao","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113431226100_B19","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113431226100_B20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2265.2008.03208.x","article-title":"Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly","volume":"69","author":"Chanson","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113431226100_B21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11102-009-0191-1","article-title":"Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension","volume":"13","author":"Melmed","year":"2010","journal-title":"Pituitary"},{"key":"key\n\t\t\t\t2019041113431226100_B22","first-page":"OR49","article-title":"Pasireotide LAR is significantly more effective than octreotide LAR at providing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, phase III study","volume":"33","author":"Bronstein","year":"2012","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041113431226100_B23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11102-008-0123-5","article-title":"Inter- and intra-observer variability in detection and progression assessment with MRI of microadenoma in Cushing's disease patients followed up after bilateral adrenalectomy","volume":"11","author":"Bahurel-Barrera","year":"2008","journal-title":"Pituitary"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/99\/4\/1282\/9047459\/jcem1282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T01:16:46Z","timestamp":1564967806000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/99\/4\/1282\/2537335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,1]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2013-3318","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718246432.793511697","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,1]]}}}